Literature DB >> 1544406

Up-regulation of the interleukin-6-signal transducing protein (gp130) by interleukin-6 and dexamethasone in HepG2 cells.

H Schooltink1, H Schmitz-Van de Leur, P C Heinrich, S Rose-John.   

Abstract

The hepatic IL-6-receptor is composed of an 80 kDa IL-6-binding protein and a 130 kDa polypeptide (gp130) believed to be involved in signal transduction. Previous experiments have shown that the 80 kDa IL-6-receptor is up-regulated by glucocorticoids, but not by IL-6. Here we demonstrate that IL-6 together with the synthetic glucocorticoid dexamethasone induces the expression of mRNA for gp130 approximately 5-fold in HepG2 cells. The induction was dose- and time-dependent. Dexamethasone alone, interferon-gamma, IL-1 alpha and IL-1 beta had no effect. A possible role for the regulation of the IL-6-signal transducing protein gp130 in various inflammatory states is proposed.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1544406     DOI: 10.1016/0014-5793(92)80552-r

Source DB:  PubMed          Journal:  FEBS Lett        ISSN: 0014-5793            Impact factor:   4.124


  10 in total

1.  Regulation of the gp80 and gp130 subunits of the IL-6 receptor by sex steroids in the murine bone marrow.

Authors:  S C Lin; T Yamate; Y Taguchi; V Z Borba; G Girasole; C A O'Brien; T Bellido; E Abe; S C Manolagas
Journal:  J Clin Invest       Date:  1997-10-15       Impact factor: 14.808

2.  Glucocorticoid-dependent induction of interleukin-6 receptor expression in human hepatocytes facilitates interleukin-6 stimulation of amino acid transport.

Authors:  C P Fischer; B P Bode; K Takahashi; K K Tanabe; W W Souba
Journal:  Ann Surg       Date:  1996-05       Impact factor: 12.969

Review 3.  Glucocorticoids and central nervous system inflammation.

Authors:  Klaus Dinkel; William O Ogle; Robert M Sapolsky
Journal:  J Neurovirol       Date:  2002-12       Impact factor: 2.643

4.  IL-6 trans-signaling licenses mouse and human tumor microvascular gateways for trafficking of cytotoxic T cells.

Authors:  Daniel T Fisher; Qing Chen; Joseph J Skitzki; Jason B Muhitch; Lei Zhou; Michelle M Appenheimer; Trupti D Vardam; Emily L Weis; Jessica Passanese; Wan-Chao Wang; Sandra O Gollnick; Mark W Dewhirst; Stefan Rose-John; Elizabeth A Repasky; Heinz Baumann; Sharon S Evans
Journal:  J Clin Invest       Date:  2011-09-19       Impact factor: 14.808

5.  Distinct effects of Broncho-Vaxom (OM-85 BV) on gp130 binding cytokines.

Authors:  M Roth; L H Block
Journal:  Thorax       Date:  2000-08       Impact factor: 9.139

Review 6.  Interleukin-6 in the injured patient. Marker of injury or mediator of inflammation?

Authors:  W L Biffl; E E Moore; F A Moore; V M Peterson
Journal:  Ann Surg       Date:  1996-11       Impact factor: 12.969

7.  Interferon-alpha down-regulates the interleukin-6 receptor in a human multiple myeloma cell line, U266.

Authors:  J C Anthes; Z Zhan; H Gilchrest; R W Egan; M I Siegel; M M Billah
Journal:  Biochem J       Date:  1995-07-01       Impact factor: 3.857

8.  Human serum amyloid A genes are expressed in monocyte/macrophage cell lines.

Authors:  S Urieli-Shoval; R L Meek; R H Hanson; N Eriksen; E P Benditt
Journal:  Am J Pathol       Date:  1994-09       Impact factor: 4.307

9.  Inhibition of IL-6+IL-6 soluble receptor-stimulated aromatase activity by the IL-6 antagonist, Sant 7, in breast tissue-derived fibroblasts.

Authors:  A Purohit; A Singh; M W Ghilchik; O Serlupi-Crescenzi; M J Reed
Journal:  Br J Cancer       Date:  2003-02-24       Impact factor: 7.640

Review 10.  Recent Advances in Electrochemical and Optical Biosensors Designed for Detection of Interleukin 6.

Authors:  Munezza Ata Khan; Mohammad Mujahid
Journal:  Sensors (Basel)       Date:  2020-01-23       Impact factor: 3.576

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.